AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of Chase Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Chase Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
1825 K Street NW, Suite 510 Washington, DC 20006
Telephone
Telephone
(202) 568-8831
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The proceeds will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson’s Disease.


Lead Product(s): Pramipexole Dihydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: CTC-501

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Chinalink Asia Holdings

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing October 20, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY